A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

Kalyan Nadiminti; Kimberly Langer; Ehsan Shabbir; Mehrdad Hefazi; Lindsay Dozeman; Yogesh Jethava; Bradley Loeffler; Hassan B AlKhateeb; Mark Litzow; Mrinal Patnaik; Mithun Shah; William Hogan; Umar Farooq; Margarida Silverman; Sarah L Mott

doi:10.1038/s41408-021-00573-6

Back

A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

Journal article

Open access

Peer reviewed

A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

Kalyan Nadiminti, Kimberly Langer, Ehsan Shabbir, Mehrdad Hefazi, Lindsay Dozeman, Yogesh Jethava, Bradley Loeffler, Hassan B AlKhateeb, Mark Litzow, Mrinal Patnaik, …

Blood cancer journal (New York), Vol.11(11), pp.183-183

11/20/2021

DOI: 10.1038/s41408-021-00573-6

PMCID: PMC8606004

PMID: 34802042

Files and links (1)

url

https://doi.org/10.1038/s41408-021-00573-6View

Published (Version of record) Open Access

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for many hematologic conditions and is associated with considerable morbidity and mortality. Therefore, prognostic tools are essential to navigate the complex patient, disease, donor, and transplant characteristics that differentially influence outcomes. We developed a novel, comprehensive composite prognostic tool. Using a lasso-penalized Cox regression model (n = 273), performance status, HCT-CI, refined disease-risk index (rDRI), donor and recipient CMV status, and donor age were identified as predictors of disease-free survival (DFS). The results for overall survival (OS) were similar except for recipient CMV status not being included in the model. Models were validated in an external dataset (n = 378) and resulted in a c-statistic of 0.61 and 0.62 for DFS and OS, respectively. Importantly, this tool incorporates donor age as a variable, which has an important role in HSCT outcomes. This needs to be further studied in prospective models. An easy-to-use and a web-based nomogram can be accessed here: https://allohsctsurvivalcalc.iowa.uiowa.edu/ .

Aged

Allografts

Disease-Free Survival

Female

Hematopoietic Stem Cell Transplantation

Humans

Male

Middle Aged

Models, Biological

Risk Assessment

Survival Rate

Details

Title: Subtitle: A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction
Creators: Kalyan Nadiminti - University of Wisconsin–Madison
Kimberly Langer - Mayo Clinic
Ehsan Shabbir - Wright State University
Mehrdad Hefazi - Mayo Clinic in Florida
Lindsay Dozeman - University of Iowa Hospitals and Clinics
Yogesh Jethava - University of Iowa Hospitals and Clinics
Bradley Loeffler - University of Iowa
Hassan B AlKhateeb - Mayo Clinic
Mark Litzow - Mayo Clinic
Mrinal Patnaik - Mayo Clinic
Mithun Shah - Mayo Clinic
William Hogan - Mayo Clinic
Umar Farooq - University of Iowa Hospitals and Clinics
Margarida Silverman - University of Iowa
Sarah L Mott - University of Iowa
Resource Type: Journal article
Publication Details: Blood cancer journal (New York), Vol.11(11), pp.183-183
DOI: 10.1038/s41408-021-00573-6
PMID: 34802042
PMCID: PMC8606004
NLM abbreviation: Blood Cancer J
ISSN: 2044-5385
eISSN: 2044-5385
Language: English
Date published: 11/20/2021
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359818102771

Metrics

22 Record Views

1 Times Cited - Web of Science

See more details